Evercore ISI initiated coverage of Edgewise Therapeutics (EWTX) with an Outperform rating and $45 price target The pipeline offers two “compelling assets” with multiple, near-term clinical readouts: sevasemten for Becker muscular dystrophy, or BMD, and Duchenne muscular dystrophy, or DMD, and EDG7500 for obstructive and non-obstructive hypertrophic cardiomyopathy, or HCM, the analyst tells investors. Both have demonstrated “promising early data” and each have multi-billion dollar sales potential, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials
- Edgewise Therapeutics reports Q3 EPS (36c), consensus (37c)
- Edgewise Therapeutics call volume above normal and directionally bullish
- Edgewise Therapeutics price target raised to $51 from $48 at Piper Sandler
- Largest borrow rate increases among liquid names